|Mr. Steven A. Kriegsman||Chairman & CEO||1.01M||N/A||1942|
|Mr. John Y. Caloz||Chief Financial Officer||535k||N/A||1952|
|Mr. Eric L. Curtis||Pres & COO||N/A||N/A||N/A|
|Dr. Felix Kratz Ph.D.||Sr. VP, Drug Devel.||N/A||N/A||1963|
|Dr. André Warnecke Ph.D.||Sr. Director of Drug Discovery||N/A||N/A||N/A|
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
CytRx Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.